These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

90 related items for PubMed ID: 3562292

  • 1. Vitamin A and tumor recurrence in bladder cancer.
    Michalek AM, Cummings KM, Phelan J.
    Nutr Cancer; 1987; 9(2-3):143-6. PubMed ID: 3562292
    [Abstract] [Full Text] [Related]

  • 2. Fluid intake and the risk of tumor recurrence in patients with superficial bladder cancer.
    Donat SM, Bayuga S, Herr HW, Berwick M.
    J Urol; 2003 Nov; 170(5):1777-80. PubMed ID: 14532774
    [Abstract] [Full Text] [Related]

  • 3. Stopping smoking might reduce tumour recurrence in nonmuscle-invasive bladder cancer.
    Chen CH, Shun CT, Huang KH, Huang CY, Tsai YC, Yu HJ, Pu YS.
    BJU Int; 2007 Aug; 100(2):281-6; discussion 286. PubMed ID: 17419696
    [Abstract] [Full Text] [Related]

  • 4. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
    Librenjak D, Situm M, Eterovic D, Dogas Z, Gotovac J.
    Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
    [Abstract] [Full Text] [Related]

  • 5. [Clinical research on prevention of recurrence of superficial bladder cancer--comparative study on clinical efficacy of bleomycin intravesical instillation and bestatin].
    Kumamoto Y, Tsukamoto T, Tamiya T, Takatsuka K, Furuya S, Yokoyama E, Honma A, Aoyama T, Tanda H, Kato S.
    Hinyokika Kiyo; 1985 Oct; 31(10):1861-83. PubMed ID: 2418659
    [Abstract] [Full Text] [Related]

  • 6. Reduced bladder cancer recurrence rate with cardioprotective aspirin after intravesical bacille Calmette-Guérin.
    Gee JR, Jarrard DF, Bruskewitz RC, Moon TD, Hedican SP, Leverson GE, Nakada SY, Messing EM.
    BJU Int; 2009 Mar; 103(6):736-9. PubMed ID: 19007364
    [Abstract] [Full Text] [Related]

  • 7. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
    Lerner SP, Tangen CM, Sucharew H, Wood D, Crawford ED.
    J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
    [Abstract] [Full Text] [Related]

  • 8. Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study.
    Denzinger S, Burger M, Walter B, Knuechel R, Roessler W, Wieland WF, Filbeck T.
    Urology; 2007 Apr; 69(4):675-9. PubMed ID: 17445650
    [Abstract] [Full Text] [Related]

  • 9. Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer.
    Messing E, Kim KM, Sharkey F, Schultz M, Parnes H, Kim D, Saltzstein D, Wilding G.
    J Urol; 2006 Aug; 176(2):500-4. PubMed ID: 16813878
    [Abstract] [Full Text] [Related]

  • 10. Early and large-dose intravesical instillation of epirubicin to prevent superficial bladder carcinoma recurrence after transurethral resection.
    Mitsumori K, Tsuchiya N, Habuchi T, Li Z, Akao T, Ohyama C, Sato K, Kato T.
    BJU Int; 2004 Aug; 94(3):317-21. PubMed ID: 15291859
    [Abstract] [Full Text] [Related]

  • 11. [Treatment of low grade and low stage urinary bladder cancer].
    Miura T, Sakuramoto T, Noguchi S, Shuin T, Moriyama M, Kubota Y.
    Hinyokika Kiyo; 1985 Feb; 31(2):265-71. PubMed ID: 4013945
    [Abstract] [Full Text] [Related]

  • 12. Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer.
    Sabichi AL, Lerner SP, Atkinson EN, Grossman HB, Caraway NP, Dinney CP, Penson DF, Matin S, Kamat A, Pisters LL, Lin DW, Katz RL, Brenner DE, Hemstreet GP, Wargo M, Bleyer A, Sanders WH, Clifford JL, Parnes HL, Lippman SM.
    Clin Cancer Res; 2008 Jan 01; 14(1):224-9. PubMed ID: 18172274
    [Abstract] [Full Text] [Related]

  • 13. Chemoprevention of superficial bladder cancer.
    Kamat AM.
    Expert Rev Anticancer Ther; 2003 Dec 01; 3(6):799-808. PubMed ID: 14686702
    [Abstract] [Full Text] [Related]

  • 14. Sustained prophylactic effect of intravesical bacille Calmette-Guérin for superficial bladder cancer: a smoothed hazard analysis in a randomized prospective study.
    Hinotsu S, Akaza H, Isaka S, Kanetake H, Kubota Y, Kuroda M, Shinohara N, Shinka T, Tachibana M, Naito S, Hirao Y, BCG Tokyo 172 Strain Study Group.
    Urology; 2006 Mar 01; 67(3):545-9. PubMed ID: 16527576
    [Abstract] [Full Text] [Related]

  • 15. [Clinical investigation on the effect of intravesical instillation of antifibrinolytic agents with bacillus Calmette-Guerin on preventing bladder cancer recurrence].
    Ding GQ, Shen ZJ, Lu J, Jin XD, Chen J, Shi SF.
    Zhonghua Wai Ke Za Zhi; 2005 Nov 15; 43(22):1457-60. PubMed ID: 16318813
    [Abstract] [Full Text] [Related]

  • 16. [Prophylactic effect of etretinate on the recurrence of superficial bladder tumors--results of a randomized control study].
    Yoshida O, Miyakawa M, Watanabe H, Mishina T, Okajima E, Hirao Y, Matushima M, Nihira H, Nakatsu H.
    Hinyokika Kiyo; 1986 Sep 15; 32(9):1349-58. PubMed ID: 3544744
    [Abstract] [Full Text] [Related]

  • 17. [Intravesical BCG therapy for superficial bladder cancer].
    Segawa N, Iwamoto Y, Azuma H, Yamamoto K, Ueda H, Katsuoka Y.
    Hinyokika Kiyo; 1998 Sep 15; 44(9):627-31. PubMed ID: 9805666
    [Abstract] [Full Text] [Related]

  • 18. [Our experience with mitomycin C in the prophylaxis of superficial bladder tumors; retrospective study].
    Moyano Calvo JL, Herrero Torres L, Melón Rey FJ, Rabadán Ruiz M, Pereira Sanz I.
    Arch Esp Urol; 1994 Oct 15; 47(8):750-4. PubMed ID: 7818293
    [Abstract] [Full Text] [Related]

  • 19. Response of multiple recurrent TaT1 bladder cancer to intravesical apaziquone (EO9): comparative analysis of tumor recurrence rates.
    Jain A, Phillips RM, Scally AJ, Lenaz G, Beer M, Puri R.
    Urology; 2009 May 15; 73(5):1083-6. PubMed ID: 19232688
    [Abstract] [Full Text] [Related]

  • 20. XIAP as a prognostic marker of early recurrence of nonmuscular invasive bladder cancer.
    Li M, Song T, Yin ZF, Na YQ.
    Chin Med J (Engl); 2007 Mar 20; 120(6):469-73. PubMed ID: 17439739
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.